Equities

Mind Medicine (MindMed) Inc

Mind Medicine (MindMed) Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)7.61
  • Today's Change0.05 / 0.66%
  • Shares traded80.00
  • 1 Year change+151.99%
  • Beta-6.6937
Data delayed at least 15 minutes, as of Nov 25 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).

  • Revenue in USD (TTM)0.00
  • Net income in USD-97.80m
  • Incorporated2010
  • Employees57.00
  • Location
    Mind Medicine (MindMed) IncOne World Trade Center, Suite 8500NEW YORK 10007United StatesUSA
  • Phone+1 (212) 220-6633
  • Fax+1 (888) 848-3972
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Monte Rosa Therapeutics Inc14.98m-119.39m521.60m103.00--2.53--34.83-1.83-1.830.22153.350.0528--33.69112,594.00-42.10---47.48-------797.26------0.00-------24.75------
IGM Biosciences Inc2.92m-219.84m528.64m198.00--7.08--181.16-3.65-3.650.04841.330.0075----13,026.79-56.45-44.66-63.54-48.20-----7,534.03-23,668.96----0.00--99.25---11.45--73.48--
Organogenesis Holdings Inc455.04m-7.38m536.93m862.00--1.9257.071.18-0.0567-0.05673.432.101.004.094.78527,886.30-1.625.46-1.976.9075.2974.94-1.624.812.746.560.18750.00-3.9417.49-68.16--67.34--
Annexon Inc0.00-117.50m543.06m84.00--1.63-----1.04-1.040.003.140.00----0.00-40.34-44.06-43.09-46.93------------0.00------5.43--62.56--
Astria Therapeutics Inc0.00-100.04m544.50m59.00--2.29-----2.09-2.090.006.050.00----0.00-36.02-64.48-37.72-68.34------------0.00-------40.62------
Ironwood Pharmaceuticals, Inc.378.42m-2.46m550.50m267.00------1.45-0.016-0.0162.39-1.950.8284--3.771,417,296.00-0.6832-4.54-1.07-5.20-----0.8248-7.81--3.882.08--7.835.02-672.50--160.10--
Humacyte Inc0.00-152.87m550.71m183.00---------1.34-1.340.00-0.53170.00----0.00-115.74---134.05-------------27.44-----100.00---825.83------
Mind Medicine (MindMed) Inc0.00-97.80m554.39m57.00--2.37-----1.99-1.990.003.210.00----0.00-42.40---49.28--------------0.0849-------68.55------
Grail Inc-100.00bn-100.00bn554.58m1.37k--0.2269----------77.93-----------47.45---48.55-------5,118.86----0.00--67.61--72.85---4.22--
Third Harmonic Bio Inc0.00-39.20m561.88m51.00--1.89-----0.9694-0.96940.006.590.00----0.00-13.36---13.66--------------0.00------12.32------
Chromadex Corp91.67m1.49m568.29m106.00394.0816.50244.326.200.01890.01891.210.45211.673.0523.51864,792.402.70-42.114.08-65.1461.4559.681.62-30.642.35--0.0004--15.9921.5070.15---36.66--
Corvus Pharmaceuticals Inc0.00-56.83m575.10m28.00--45.04-----0.9262-0.92620.000.19830.00----0.00-102.63-38.31-199.23-43.34-----------34.330.00------34.57---37.45--
Savara Inc0.00-82.94m576.64m37.00--2.92-----0.4452-0.44520.001.170.00----0.00-39.41-36.86-41.56-39.54-------102,587.50----0.1175-------43.38--15.91--
Sana Biotechnology Inc0.00-305.81m582.73m328.00--1.89-----1.41-1.410.001.310.00----0.00-51.36-38.99-56.78-42.70------------0.00-------5.11--112.71--
Tourmaline Bio Inc0.00-48.85m590.04m44.00--1.90-----1.68-1.680.0012.520.00----0.00-20.37---21.05--------------0.00------42.99------
Data as of Nov 25 2024. Currency figures normalised to Mind Medicine (MindMed) Inc's reporting currency: US Dollar USD

Institutional shareholders

52.63%Per cent of shares held by top holders
HolderShares% Held
Commodore Capital LPas of 30 Sep 20248.00m10.91%
Deep Track Capital LPas of 30 Sep 20247.07m9.63%
BlackRock Fund Advisorsas of 30 Sep 20245.18m7.06%
Blackstone Alternative Asset Management LPas of 30 Sep 20243.91m5.34%
Driehaus Capital Management LLCas of 30 Sep 20243.89m5.31%
Octagon Capital Advisors LPas of 30 Sep 20243.02m4.12%
Marshall Wace LLPas of 30 Sep 20242.29m3.12%
SSgA Funds Management, Inc.as of 30 Sep 20241.81m2.48%
The Vanguard Group, Inc.as of 30 Sep 20241.75m2.38%
Geode Capital Management LLCas of 30 Sep 20241.68m2.29%
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.